Eintrag weiter verarbeiten
Targeting of histone deacetylases in brain tumors
Gespeichert in:
| Zeitschriftentitel: | CNS Oncology |
|---|---|
| Personen und Körperschaften: | , , |
| In: | CNS Oncology, 2, 2013, 4, S. 359-376 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Future Medicine Ltd
|
| Schlagwörter: |
| author_facet |
Ecker, Jonas Witt, Olaf Milde, Till Ecker, Jonas Witt, Olaf Milde, Till |
|---|---|
| author |
Ecker, Jonas Witt, Olaf Milde, Till |
| spellingShingle |
Ecker, Jonas Witt, Olaf Milde, Till CNS Oncology Targeting of histone deacetylases in brain tumors General Medicine |
| author_sort |
ecker, jonas |
| spelling |
Ecker, Jonas Witt, Olaf Milde, Till 2045-0907 2045-0915 Future Medicine Ltd General Medicine http://dx.doi.org/10.2217/cns.13.24 <jats:p> SUMMARY Histone deacetylase inhibitors (HDACis) have fascinated researchers in almost all fields of oncology for many years owing to their pleiotropic effects on nearly every aspect of cancer biology. Since the approval of the first HDACi vorinostat for the treatment of cutaneous T-cell leukemia in 2006, more than a hundred clinical trials have been initiated with a HDACi as a single agent or in combination therapy. Although a number of epigenetic and nonepigenetic molecular mechanisms of action have been proposed, biomarkers for response prediction and patient selection are still lacking. One of the inherent problems in the field of HDACis is their ‘reverse‘ history of drug development: these compounds reached clinical application at an early stage, before the biology of their targets, HDAC1–11, was sufficiently understood. This review summarizes the current knowledge on the human family of HDACs as drug targets in pediatric and adult brain tumors, the efficacy and molecular action of HDACis in preclinical models, as well as the current status of the clinical development of these compounds in the field of neuro-oncology. </jats:p> Targeting of histone deacetylases in brain tumors CNS Oncology |
| doi_str_mv |
10.2217/cns.13.24 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjIxNy9jbnMuMTMuMjQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjIxNy9jbnMuMTMuMjQ |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
Future Medicine Ltd, 2013 |
| imprint_str_mv |
Future Medicine Ltd, 2013 |
| issn |
2045-0907 2045-0915 |
| issn_str_mv |
2045-0907 2045-0915 |
| language |
English |
| mega_collection |
Future Medicine Ltd (CrossRef) |
| match_str |
ecker2013targetingofhistonedeacetylasesinbraintumors |
| publishDateSort |
2013 |
| publisher |
Future Medicine Ltd |
| recordtype |
ai |
| record_format |
ai |
| series |
CNS Oncology |
| source_id |
49 |
| title |
Targeting of histone deacetylases in brain tumors |
| title_unstemmed |
Targeting of histone deacetylases in brain tumors |
| title_full |
Targeting of histone deacetylases in brain tumors |
| title_fullStr |
Targeting of histone deacetylases in brain tumors |
| title_full_unstemmed |
Targeting of histone deacetylases in brain tumors |
| title_short |
Targeting of histone deacetylases in brain tumors |
| title_sort |
targeting of histone deacetylases in brain tumors |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.2217/cns.13.24 |
| publishDate |
2013 |
| physical |
359-376 |
| description |
<jats:p> SUMMARY Histone deacetylase inhibitors (HDACis) have fascinated researchers in almost all fields of oncology for many years owing to their pleiotropic effects on nearly every aspect of cancer biology. Since the approval of the first HDACi vorinostat for the treatment of cutaneous T-cell leukemia in 2006, more than a hundred clinical trials have been initiated with a HDACi as a single agent or in combination therapy. Although a number of epigenetic and nonepigenetic molecular mechanisms of action have been proposed, biomarkers for response prediction and patient selection are still lacking. One of the inherent problems in the field of HDACis is their ‘reverse‘ history of drug development: these compounds reached clinical application at an early stage, before the biology of their targets, HDAC1–11, was sufficiently understood. This review summarizes the current knowledge on the human family of HDACs as drug targets in pediatric and adult brain tumors, the efficacy and molecular action of HDACis in preclinical models, as well as the current status of the clinical development of these compounds in the field of neuro-oncology. </jats:p> |
| container_issue |
4 |
| container_start_page |
359 |
| container_title |
CNS Oncology |
| container_volume |
2 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343242560241670 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:48:34.357Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Targeting+of+histone+deacetylases+in+brain+tumors&rft.date=2013-07-01&genre=article&issn=2045-0915&volume=2&issue=4&spage=359&epage=376&pages=359-376&jtitle=CNS+Oncology&atitle=Targeting+of+histone+deacetylases+in+brain+tumors&aulast=Milde&aufirst=Till&rft_id=info%3Adoi%2F10.2217%2Fcns.13.24&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343242560241670 |
| author | Ecker, Jonas, Witt, Olaf, Milde, Till |
| author_facet | Ecker, Jonas, Witt, Olaf, Milde, Till, Ecker, Jonas, Witt, Olaf, Milde, Till |
| author_sort | ecker, jonas |
| container_issue | 4 |
| container_start_page | 359 |
| container_title | CNS Oncology |
| container_volume | 2 |
| description | <jats:p> SUMMARY Histone deacetylase inhibitors (HDACis) have fascinated researchers in almost all fields of oncology for many years owing to their pleiotropic effects on nearly every aspect of cancer biology. Since the approval of the first HDACi vorinostat for the treatment of cutaneous T-cell leukemia in 2006, more than a hundred clinical trials have been initiated with a HDACi as a single agent or in combination therapy. Although a number of epigenetic and nonepigenetic molecular mechanisms of action have been proposed, biomarkers for response prediction and patient selection are still lacking. One of the inherent problems in the field of HDACis is their ‘reverse‘ history of drug development: these compounds reached clinical application at an early stage, before the biology of their targets, HDAC1–11, was sufficiently understood. This review summarizes the current knowledge on the human family of HDACs as drug targets in pediatric and adult brain tumors, the efficacy and molecular action of HDACis in preclinical models, as well as the current status of the clinical development of these compounds in the field of neuro-oncology. </jats:p> |
| doi_str_mv | 10.2217/cns.13.24 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjIxNy9jbnMuMTMuMjQ |
| imprint | Future Medicine Ltd, 2013 |
| imprint_str_mv | Future Medicine Ltd, 2013 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 2045-0907, 2045-0915 |
| issn_str_mv | 2045-0907, 2045-0915 |
| language | English |
| last_indexed | 2024-03-01T16:48:34.357Z |
| match_str | ecker2013targetingofhistonedeacetylasesinbraintumors |
| mega_collection | Future Medicine Ltd (CrossRef) |
| physical | 359-376 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | Future Medicine Ltd |
| record_format | ai |
| recordtype | ai |
| series | CNS Oncology |
| source_id | 49 |
| spelling | Ecker, Jonas Witt, Olaf Milde, Till 2045-0907 2045-0915 Future Medicine Ltd General Medicine http://dx.doi.org/10.2217/cns.13.24 <jats:p> SUMMARY Histone deacetylase inhibitors (HDACis) have fascinated researchers in almost all fields of oncology for many years owing to their pleiotropic effects on nearly every aspect of cancer biology. Since the approval of the first HDACi vorinostat for the treatment of cutaneous T-cell leukemia in 2006, more than a hundred clinical trials have been initiated with a HDACi as a single agent or in combination therapy. Although a number of epigenetic and nonepigenetic molecular mechanisms of action have been proposed, biomarkers for response prediction and patient selection are still lacking. One of the inherent problems in the field of HDACis is their ‘reverse‘ history of drug development: these compounds reached clinical application at an early stage, before the biology of their targets, HDAC1–11, was sufficiently understood. This review summarizes the current knowledge on the human family of HDACs as drug targets in pediatric and adult brain tumors, the efficacy and molecular action of HDACis in preclinical models, as well as the current status of the clinical development of these compounds in the field of neuro-oncology. </jats:p> Targeting of histone deacetylases in brain tumors CNS Oncology |
| spellingShingle | Ecker, Jonas, Witt, Olaf, Milde, Till, CNS Oncology, Targeting of histone deacetylases in brain tumors, General Medicine |
| title | Targeting of histone deacetylases in brain tumors |
| title_full | Targeting of histone deacetylases in brain tumors |
| title_fullStr | Targeting of histone deacetylases in brain tumors |
| title_full_unstemmed | Targeting of histone deacetylases in brain tumors |
| title_short | Targeting of histone deacetylases in brain tumors |
| title_sort | targeting of histone deacetylases in brain tumors |
| title_unstemmed | Targeting of histone deacetylases in brain tumors |
| topic | General Medicine |
| url | http://dx.doi.org/10.2217/cns.13.24 |